Screener
Kura Oncology KURA Q2 2026 earnings
Reported August 12, 2026 · After market close
Revenue$20.9MBeat by $711.4K
EPS-$0.77Beat by $0.11
Revenue estimate$20.2M
EPS estimate-$0.88
“Increasing physician preference for KOMZIFTI, combined with outstanding commercial execution and encouraging frontline data, establish a strong foundation for ziftomenib as a potential market leader throughout the AML treatment continuum. In parallel, darlifarnib is emerging as a differentiated precision combination platform across multiple targeted therapies in major solid tumor indications. Together, these programs position Kura to build long-term value while advancing innovative therapies for patients with significant unmet need.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$23.8M
EPS estimate-$0.84
Valuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Kura Oncology report Q2 2026 earnings?
- Kura Oncology (KURA) reported Q2 2026 earnings on August 12, 2026 after market close.
- What were Kura Oncology's Q2 2026 revenue and EPS?
- Kura Oncology reported revenue of $20.9M and eps of $-0.77 for Q2 2026.
- Did Kura Oncology beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $20.2M by $711.4K. EPS beat the consensus estimate of $-0.88 by $0.11.
- How did Kura Oncology's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 36.5% from $15.3M a year earlier and eps declined 2.7% from $-0.75.
- Where can I find Kura Oncology's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-346856) and the 10-Q periodic report (0001193125-26-346884) directly on SEC EDGAR. The filing index links above go to sec.gov.
